On 26 November 2020, the European Commission ("Commission") announced that it had fined the pharmaceutical companies Teva and Cephalon EUR 60.5 million for agreeing to delay for several years the market entry of a cheaper generic version of Cephalon's drug for sleep disorders, modafinil, after Cephalon's main patents had expired, in breach of Article 101 TFEU (the prohibition of anticompetitive agreements). WHAT YOU NEED TO KNOW - KEY TAKEAWAYS The decision completes the cycle of pay-for-delay pharmaceutical investigations launched with
Share on
|
|
The EU Commission fines pharmaceutical companies for pay-for-delay agreement (Teva / Cephalon)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
